Shares of Evgen Pharma PLC (LON:EVG) shot up 21.2% during trading on Wednesday . The company traded as high as GBX 19.70 ($0.26) and last traded at GBX 19.70 ($0.26). 294,125 shares traded hands during mid-day trading, an increase of 42% from the average session volume of 207,445 shares. The stock had previously closed at GBX 16.25 ($0.21).
Separately, FinnCap began coverage on Evgen Pharma in a research report on Tuesday, April 2nd. They issued a “corporate” rating and a GBX 45 ($0.59) price target on the stock.
The stock has a market capitalization of $19.55 million and a P/E ratio of -6.58.
Evgen Pharma Company Profile (LON:EVG)
Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer.
Read More: What are the benefits of momentum investing?
Receive News & Ratings for Evgen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.